HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Rabeprazole combined with hydrotalcite is effective for patients with bile reflux gastritis after cholecystectomy.

AbstractBACKGROUND:
Regardless of surgical technique, patients who have undergone cholecystectomy appear to be predisposed to the development of bile reflux gastritis.
OBJECTIVE:
To assess the efficacy of rabeprazole and hydrotalcite in patients with bile reflux gastritis after cholecystectomy.
METHODS:
Postcholecystectomy patients with bile reflux gastritis confirmed by endoscopy and 24 h gastric bilirubin monitoring were randomly assigned to one of four eight-week treatments: observation (group A), rabeprazole alone (group B), hydrotalcite alone (group C) and rabeprazole in combination with hydrotalcite (group D). Endoscopy and 24 h gastric bilirubin monitoring were repeated in all patients after treatment. Dyspeptic symptoms of abdominal pain, bloating, heartburn, bitter taste, endoscopic and histological finding, and biliary reflux were evaluated before and after treatment.
RESULTS:
After administering medication, patient symptoms in groups B, C and D were relieved - most significantly in group D (P<0.05). There were no significant differences in endoscopic hyperemia and histological inflammation among the groups (P>0.05). However, histological activity, the number of reflux episodes and the number of reflux episodes lasting longer than 5 min were significantly decreased only in group D (P<0.05). The total per cent of bilirubin absorption (value of 0.14 units or greater) time was decreased in groups B, C and D, and most significantly in group D (P<0.05).
CONCLUSION:
Rabeprazole combined with hydrotalcite is an effective therapeutic option in the treatment of patients with bile reflux gastritis after cholecystectomy.
AuthorsHuimin Chen, Xiaobo Li, Zhizheng Ge, Yunjie Gao, Xiaoyu Chen, Yun Cui
JournalCanadian journal of gastroenterology = Journal canadien de gastroenterologie (Can J Gastroenterol) Vol. 24 Issue 3 Pg. 197-201 (Mar 2010) ISSN: 0835-7900 [Print] Canada
PMID20352149 (Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Antacids
  • Anti-Ulcer Agents
  • hydrotalcite
  • Rabeprazole
  • Aluminum Hydroxide
  • Magnesium Hydroxide
  • Bilirubin
Topics
  • 2-Pyridinylmethylsulfinylbenzimidazoles (administration & dosage, therapeutic use)
  • Adult
  • Aged
  • Aluminum Hydroxide (administration & dosage, therapeutic use)
  • Antacids (administration & dosage, therapeutic use)
  • Anti-Ulcer Agents (administration & dosage, therapeutic use)
  • Bile Reflux (drug therapy, etiology)
  • Bilirubin (metabolism)
  • Cholecystectomy (adverse effects)
  • Drug Therapy, Combination
  • Female
  • Gastritis (drug therapy, etiology)
  • Gastroscopy
  • Humans
  • Magnesium Hydroxide (administration & dosage, therapeutic use)
  • Male
  • Middle Aged
  • Rabeprazole
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: